Document Type
Patent
Publication Date
December 2014
Patent Number
8906869
CPC
C07H 19/04(20130101), A61K 31/706(20130101), G01N 33/57449(20130101)
Abstract
The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug. The invention further encompasses a number of miRNAs, which are altered in human ovarian cancer, with the most significantly deregulated miRNAs being miR-214, -199a*, -200a, -100, -12Sb, and let-7 cluster. Further, the invention illustrates that frequent deregulation of miR-214, -199a*, -200a and -100 in ovarian cancers and their alterations are associated with high grade and late stage tumor.
Application Number
13/936,864
Recommended Citation
Cheng, Jin Q., "Effective treatment of ovarian cancer using triciribine and related compounds" (2014). USF Patents. 176.
https://digitalcommons.usf.edu/usf_patents/176
Assignees
University of South Florida
Filing Date
07/08/2013
Primary/U.S. Class
514/43
